Seeking Alpha

Debra Fiakas, CFA

 
View Debra Fiakas, CFA's Comments BY TICKER:
  • What BioSante's Balance Sheet Says About Future R&D [View article]
    You outline the typical sequence of tactics and it may very well be strategy of BioSante. I also agree with you on the buyout prospects.
    Jun 7 11:08 AM | Likes Like |Link to Comment
  • What BioSante's Balance Sheet Says About Future R&D [View article]
    You have pointed out an important element in the GVAX story. Physicians have been supporting a variety of studies and trials related to GVAX and BioSante has benefited from that. While numerous, these studies are not the large, double-blinded, randomized clinical trials that are needed to impress FDA reviewers who might approve GVAX for commercial use. BioSante management is apparently looking at various options, including a strategic partner, to pay for those important clinical trials for GVAX. Unfortunately, this particular option means BioSante will have to give up some of the ownership or offer royalities. There is no free lunch in pharma.
    Mar 13 02:23 PM | Likes Like |Link to Comment
More on ANIP by Debra Fiakas, CFA
COMMENTS STATS
115 Comments
19 Likes